Sep 2, 2026LATEST SOURCED
other
Typewriter aims to engineer immune cells inside the body
Investors undisclosed
Amount$56MValuationUndisclosed
← Company explorer
Captables
TY
COMPANY PROFILE
Typewriter
Tracked in the Captables newsroom
Historical ranking valuationUndisclosedNo reviewed valuation record
Disclosed primary funding in this record
Not establishedSum of non-overlapping disclosed USD amounts in confirmed primary financing entries in this record, including separately labeled equity components; not verified lifetime funding. Excludes amounts already included in a later round, announced, reported, database-only, debt, secondary and unclassified events.
0 confirmed primary rounds with disclosed USD amounts · Record through 2026-11-01THE BUSINESS
Get to know Typewriter.
Founded in February 2022, Typewriter builds on University of Tokyo scientist Haruhiko Fujiwara's research into gene-inserting elements known as retrotransposons. It operates research facilities in Tokyo and Cambridge. Its announcement describes proof-of-concept work in humanized mouse models and plans for its first non-human-primate studies in late 2026. For this company, those research milestones are more informative than a customer count: the immediate work is developing a drug candidate and testing the underlying approach, not scaling an existing treatment business.
Business context from our coverage From coverage published Sep 4, 2026Valuation history
Valuations reported at the time of each round.
No dated financing valuation has passed into this record.
Funding history
Funding rounds, debt and other financing events.
1sourced event · record as of 2026-11-01
Headline association; not a reviewed issuer link. Unlinked article observations are not independently reconciled financing events. This is covered public-source history, not an exhaustive issuer ledger.
Financing participants
Investors, lenders and other parties named in funding announcements.
No named participant has been added to this company’s public financing record.
Ownership evidence
Opening ownership research…
Captables coverage
Startups / Captables
Typewriter raises $56M to develop gene therapies that work inside the body
Typewriter Therapeutics is developing RNA-based medicines that would insert therapeutic genes directly into a patient's cells. Its first programs target engineered immune cells and inherited liver disease, with initial primate studies planned for late 2026.
Captables Newsroom · 57d ago